Role SGLT2 inhibitor therapy in patients with transthyretin cardiac amyloidosis: a GRADE assessed systematic review and meta-analysis

Key Points

• SGLT2 inhibitors enhance survival and health outcomes in patients with cardiac amyloidosis, emphasizing treatment potential.
• The systematic review and meta-analysis aggregate findings from several observational studies, revealing a significant impact.
• Randomised controlled trials are necessary to validate these findings and ascertain definitive clinical interventions.
• These results highlight the potential role of therapies in managing transthyretin amyloidosis and cardiovascular health.

Abstract